Answers are grounded in this paper and cite their sources.
Introduction: Monitoring molecular markers of Plasmodium falciparum resistance to antimalarial drugs is a major challenge in the global fight against malaria. Aim: This study aimed to determine polymorphisms in the Pfmdr1 and Pfk13 genes and their associations with clinical and biological characteristics among patients from Bouaflé, Bondoukou and Séguéla (Côte d’Ivoire). Methods: This cross-sectional study was conducted from May to November 2019 among patients from the three localities. Only patients with a positive thick blood smear and confirmed P. falciparum monoinfection were included. Polymorphisms in the Pfmdr1 and Pfk13 genes were determined by Sanger sequencing. Associations between mutant profiles and sex, age and parasite density were assessed using Pearson’s chi-squared (χ²) test or Fisher’s exact test (when expected counts were < 5), followed by logistic regression for Pfmdr1 only. Results: The Pfmdr1 mutant profile was observed in 63.0% of isolates (46/73; 95% CI: 50.9–74.0), compared with 11.3% (6/53; 95% CI: 4.3–23.0) for Pfk13. No significant associations were found between the Pfmdr1 mutant profile and age (OR = 1.04; p = 0.184), sex (OR = 0.90; p = 0.845) or parasite density (OR = 1.95; p = 0.131). Median parasite densities did not differ significantly between patients infected with mutant and wild-type parasites for either Pfk13 (4,581 vs. 6,000; p = 0.574) or Pfmdr1 (7,828 vs. 3,000; p = 0.117). Conclusion: This study provides insight into the relationship between Pfmdr1 and Pfk13 polymorphisms in P. falciparum and patients’ clinical and biological characteristics. These findings support continued molecular surveillance of these two markers.
No takes yet. Share an insight, caveat, or question.
Kouakou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: